Cas:13362-52-2 1,13-Tridecanediol manufacturer & supplier

We serve Chemical Name:1,13-Tridecanediol CAS:13362-52-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,13-Tridecanediol

Chemical Name:1,13-Tridecanediol
CAS.NO:13362-52-2
Synonyms:tridecane-1,13-diol;Tridecane-1,13-diol
Molecular Formula:C13H28O2
Molecular Weight:216.36000
HS Code:2905399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:343.889ºC at 760 mmHg
Density:0.909 g/cm3
Index of Refraction:1.461
PSA:40.46000
Exact Mass:216.20900
LogP:3.26210

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like tridecane-1,13-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tridecane-1,13-diol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tridecane-1,13-diol Use and application,tridecane-1,13-diol technical grade,usp/ep/jp grade.


Related News: The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 1,13-Tridecanediol manufacturer Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. 1,13-Tridecanediol supplier ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. 1,13-Tridecanediol vendor The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 1,13-Tridecanediol factory The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study.